• GlucoTrack’s wholly owned subsidiary Lōkahi Therapeutics expanded its ai² Futures Lab pipeline-sourcing program focused on shelved or under-prioritized drug assets.
• First-year output: more than 45 late-stage therapeutic opportunities screened on a budget of about USD 33,000.
• Five opportunities moved into active company discussions; evaluated assets represented more than USD 500 million in prior biopharma investment.
• Program scale-up targets 12 university collaborations for the 2026-2027 academic year, up from six, with 100% retention of inaugural partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260731301672) on July 31, 2026, and is solely responsible for the information contained therein.